Work

Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report

Year: 2024

Type: article

Abstract: Rituximab (RTX) is a monoclonal antibody that targets CD20 on B cells and is used to reduce the relapse risk in neuromyelitis optica spectrum disorder (NMOSD). Some patients experience relapse or exacerbation shortly after RTX treatment. We report a 54-year-old female with seronegative NMOSD who relapsed soon after RTX treatment.

Source: Annals of Clinical Neurophysiology

DOI: 10.14253/acn.24001

Authors: Juhee Lee, Yoon-Ho Hong

Institutions: Kangwon National University, Kangwon National University Hospital

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4402889729

FWCI: 0.265

Cites: 9

Cited by: 1

Related to: 10